<i id='6E344895FC'><strike id='6E344895FC'><tt id='6E344895FC'><pre id='6E344895FC'></pre></tt></strike></i>
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
MikeReddyforSTATArtificialintelligenceisoftendescribedasablackbox:anunknowable,mysteriousforcethatop
read more
ATTAKENARE/AFP/GettyImagesShouldinsurancecoverbreastaugmentation,theprocedurecommonlyknownasaboobjob
read more
DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio
read moreAdobeDespitegroundbreakingadvancesinbasicandclinicalscienceandtechnology,clinicaltrialmethodshavenot
